Safety of SGLT-2 Inhibitors in Heart Failure for Adults with Congenital Heart Disease
Author Information
Author(s): Kheiwa Ahmed, Ssembajjwe Brian, Chatta Payush, Nageotte Stephen, Abramov Dmitry
Primary Institution: Loma Linda University
Hypothesis
The study aims to evaluate the safety of SGLT-2 inhibitors in adult congenital heart disease patients with heart failure.
Conclusion
The use of SGLT-2 inhibitors in a small cohort of adult congenital heart disease patients appears safe and well tolerated.
Supporting Evidence
- 61% of patients had moderate complexity congenital heart disease.
- Post initiation, there were no significant differences in systolic blood pressure, sodium level, and creatinine level.
- There was a statistically significant decline in weight after SGLT-2i initiation.
Takeaway
This study looked at 18 adults with heart problems from birth who took a new medicine to help their heart. It found that the medicine was safe for them.
Methodology
A retrospective, single center analysis of 18 patients with adult congenital heart disease and heart failure who were initiated on SGLT-2 inhibitors.
Potential Biases
Practice variability between ACHD centers may limit generalizability.
Limitations
The study is limited by its small sample size and being a single center, non-randomized cohort.
Participant Demographics
The average age of participants was 37 years, with a mix of moderate and great complexity congenital heart disease.
Statistical Information
P-Value
0.0039
Statistical Significance
p=0.0039
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website